Priska Pharma

Online provider of nutritional supplements and medicines for pregnant and lactating women in India.

About Priska Pharma

Priska Pharma is a Healthcare company. Online provider of nutritional supplements and medicines for pregnant and lactating women in India. Its Indian entity Priska Pharma Private Limited reported revenue of ₹2.09 Cr. Priska Pharma offers products and services including FOLIPREG® and Myramax® MOM. Its focus areas include E-commerce, Online Pharmacy, Health Retail Services and Pharmaceuticals.

Company details

Priska Pharma is identified as a provider of nutritional supplements and medicines that are directed towards pregnant and lactating women, with an online platform where products like FOLIPREG and Myramax are listed for purchase. Addresses in New Delhi, NOIDA, and PATNA are noted, along with services such as secure payments and fast shipping under specified terms. Customer support is made available through email and phone during designated hours, ensuring assistance is extended without promotional emphasis. The companys operations are observed to focus on maternal health, with policies on privacy and refunds being outlined for transparency.

Key Metrics
  • Indian entity revenue
    ₹2.09 Cr

    FY 2025 · +36% YoY

  • Indian entity net profit
    ₹76.7 Lakh

    FY 2025 · 37% margin

  • Indian entity EBITDA
    ₹1.07 Cr

    FY 2025 · 51% margin

Products & Services of Priska Pharma

Priska Pharma offers a comprehensive portfolio of products and services, including FOLIPREG® and Myramax® MOM.

FOLIPREG®
Nutritional Supplements

Nutritional supplements for pregnant women are provided to support health needs.

Myramax® MOM
Nutritional Supplements

Powder-based medicines for lactating women are offered in various flavors to aid wellness.

Board of directors of Priska Pharma Private Limited (Priska Pharma)

Priska Pharma Private Limited is the primary company behind Priska Pharma. The board of Priska Pharma Private Limited currently have 5 directors; the longest-serving is Amod Kumar, appointed in 2023. 4 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Amod Kumar
DIN 09815430
Director21 Jan 20233 yrs 9 moPriska Pharma Private Limited
Vikash Pandey
DIN 09815272
Director21 Jan 20233 yrs 9 moPriska Pharma Private Limited
Kundan Kumar
DIN 10748825
Additional Director31 Aug 20242 yrs 2 moPriska Pharma Private Limited
Ajeet Kumar
DIN 10748826
Additional Director31 Aug 20242 yrs 2 moPriska Pharma Private Limited
Manas Kumar Sircar
DIN 11049600
Additional Director25 Apr 20251 yr 6 moPriska Pharma Private Limited

Financials of Priska Pharma

Figures of Priska Pharma Private Limited, the primary company behind Priska Pharma, for FY 2025. Revenue was ₹2.09 Cr (+36% year on year). Net profit was ₹76.7 Lakh (37% margin). EBITDA was ₹1.07 Cr (51% margin). Revenue has grown at a compounded annual rate of +13% over three years and +10% over five years.

  • ₹2.09 CrRevenue · FY 2025 · +36% YoY
  • ₹76.7 LakhNet profit · 37% margin
  • ₹1.07 CrEBITDA · 51% margin
  • ₹10 LakhPaid-up capital
  • +13%Revenue CAGR, 3 years
  • +10%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Priska Pharma Private Limited are on its company page.

Premium access

Detailed financial statements for Priska Pharma

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • âś“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • âś“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • âś“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Priska Pharma

The primary company behind Priska Pharma, Priska Pharma Private Limited, reported revenue of ₹2.09 Cr for FY 2025, up 36% year on year.

Priska Pharma is identified as a provider of nutritional supplements and medicines that are directed towards pregnant and lactating women, with an online platform where products like FOLIPREG and Myramax are listed for purchase. Addresses in New Delhi, NOIDA, and PATNA are noted, along with services such as secure payments and fast shipping under specified terms. Customer support is made available through email and phone during designated hours, ensuring assistance is extended without promotional emphasis. The companys operations are observed to focus on maternal health, with policies on privacy and refunds being outlined for transparency.

Priska Pharma offers FOLIPREG® and Myramax® MOM.

Priska Pharma operates through Priska Pharma Private Limited.

The legal entities of Priska Pharma currently have 5 directors, including Amod Kumar, Vikash Pandey, Kundan Kumar and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available